Wall Street Journal

Samsung BioLogics Prices Nearly $2 Billion IPO at Top of Range
Wall Street Journal
SEOUL—Samsung Group’s contract drug-manufacturing arm said Friday that it would price its initial public offering at the top end of its range, putting it on track to raise 2.250 trillion Korean won ($1.96 billion) in a debut early next month that
Samsung BioLogics prices $1.97 billion IPO, S.Korea’s second largestReuters
Samsung Biologics prices 2.25t won IPO at high end of rangeTHE BUSINESS TIMES

all 6 news articles »

%d bloggers like this: